Vitae Pharmaceuticals (NASDAQ:VTAE) Earns News Sentiment Score of 0.37

News headlines about Vitae Pharmaceuticals (NASDAQ:VTAE) have trended positive this week, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vitae Pharmaceuticals earned a news sentiment score of 0.37 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

Vitae Pharmaceuticals (NASDAQ VTAE) opened at 21.00 on Tuesday.

WARNING: This piece of content was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/07/18/vitae-pharmaceuticals-vtae-receiving-favorable-news-coverage-study-shows-updated-updated.html.

Vitae Pharmaceuticals Company Profile

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply